Health-related quality of life as an endpoint in oncology phase I trials: a systematic review.
Fiche publication
Date publication
avril 2019
Journal
BMC cancer
Auteurs
Lien Pubmed
Résumé
Phase I trials aim to identify the recommended dose for further development. Health-related quality of life (HRQoL) could be a complement to the usual National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale to detect adverse events and define the doses. The objective of this study is to review the phase I in oncology which used HRQoL as endpoint.
Mots clés
Endpoint, Health-related quality of life, Phase I trial, Recommended phase II dose
Référence
BMC Cancer. 2019 Apr 16;19(1):361